Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Illumina Unveils Strategic Roadmap for Market Expansion

Published: Saturday, February 01, 2014
Last Updated: Saturday, February 01, 2014
Bookmark and Share
Company positions for growth in key genomics segments, introduces new workflow solutions at investor day.

Illumina, Inc. has unveiled a strategic roadmap for moving next-generation sequencing (NGS) into new markets, leveraging its technology leadership and new organizational alignment around those markets to drive growth.

During an investor day where executives presented plans for this growth, Illumina also shared workflow innovations designed to simplify the sequencing experience and new market solutions derived from the company’s sample to answer technology base.

“Earlier this week we announced two transformative platforms that redefine next-generation sequencing, with the addition of the NextSeq™ 500 System and the HiSeq® X Ten to our market leading portfolio. Today we previewed additional innovations that position us to seize opportunities across research and clinical markets, as well as to deliver the industry’s simplest, most efficient sequencing experience to our customers,” said Jay Flatley, Illumina’s Chief Executive Officer.

Expanding the Use of Next-Generation Sequencing (NGS)
Illumina shared the following strategies and innovations around its core market targets.
In reproductive health, Illumina will expand its offerings based on the verifi® laboratory-developed non-invasive prenatal test (NIPT), submitting an IVD version on the HiSeq® 2500 system for FDA premarket approval by the end of 2014. It also will offer an NGS-based solution for preimplantation genetic screening, VeriSeq™ PGS, launching initially on the MiSeq® system, as well as an array-based karyomapping single gene preimplantation genetic diagnosis (PGD) solution to identify embryos with genes associated with severe genetic disorders.
In oncology, the company previewed a targeted sequencing strategy that includes supporting the clinical community with content. Illumina is also working in collaboration with the oncology community to develop test guidelines and infrastructure to build actionable cancer genomics solutions.
In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current technologies. Additionally, the company introduced the MiSeq® Forensic Genomics System (MiSeq FGx), the first targeted forensic NGS system, which will simultaneously interrogate short tandem repeats and other valuable genetic markers to provide more comprehensive identification information from both challenging and standard biological samples. The complete sample to answer solution, including consumables and software, is expected to be available in the first six months of 2014.

Simplifying the Sample to Answer Experience
Illumina previewed the following products that simplify the end-user experience for sample preparation and analytics and further solidify the technology tool kit that can be used across markets to address customers’ needs for integration.

• NeoPrep™ is a push-button library preparation system that provides a radically simpler workflow to go from DNA or RNA to libraries ready for sequencing. It will prepare up to 16 libraries per run, starting from as little as 1ng of input for some assays. The first kits for NeoPrep will be TruSeq PCR-Free and TruSeq Nano, with other TruSeq and Nextera kits to follow. NeoPrep, expected to be available summer 2014, is an important step on the path to offering integrated, sample to answer solutions.
• BaseSpace® OnSite provides the BaseSpace® experience in a simple informatics appliance, enabling NGS users to securely stream data directly to a local solution for storing, analyzing, and interpreting genomic sequence data. BaseSpace® Onsite represents a turnkey solution and will be available in the first quarter of 2014.
• BaseSpace® Core Apps transform sequence data processing into a simple push-button process for the most frequently used sequencing applications. These highly optimized apps eliminate time spent configuring and maintaining software, and support RNA-sequencing, exome analysis, whole genome sequencing, and tumor/normal analysis. BaseSpace® Core Apps are available for BaseSpace® including BaseSpace® Onsite.

Paving the Way for Genomics in the Clinic
In November 2013, Illumina became the first company to receive FDA premarket clearance for a next-generation sequencing platform with its MiSeqDx system. Illumina will continue to pave the way for NGS in regulated markets with further submissions to the FDA, beginning with NIPT on the HiSeq® 2500, while also driving standards for the use of NGS in the clinic. In addition, the company will continue to build the infrastructure and means with which to deliver a best-in-class regulated products pipeline through its IVD Development group.

“Illumina’s technology is already making an impact in identifying undiagnosed diseases, and we will soon see it transforming fields like oncology and complex disease,” said Francis deSouza, President of Illumina. “The strategic roadmap presented today demonstrates our commitment to making NGS ubiquitous across markets, delivering simplified and integrated solutions to our customers, and paving the way for a new era in health care.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Illumina Completes Acquisition of GenoLogics
Illumina’s to drive the adoption of sequencing in new markets and improve the genomic workflow.
Wednesday, September 02, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina Accelerator Invests in Second Class of Genomics Startups
Startups selected from Spain, Oregon, and California to advance breakthrough applications.
Thursday, August 06, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Biomed Realty and Illumina Announce New Build-to-Suit Laboratory Building
New building to be located in scientific research park, Granta Park, and will serve as Illumina’s new European headquarters.
Friday, June 26, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina, Merck KGaA and Genea Form the Global Fertility Alliance
Global fertility alliance will identify and work on improvements of fertility-related laboratory processes.
Tuesday, June 09, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos